MOLOGNI LUCA
- U08, Floor: 4, Room: LABORATORIO 4.10
- U08, Floor: 4, Room: 4043
Publications
Civettini, I., Zappaterra, A., Corti, P., Messina, A., Aroldi, A., Biondi, A., et al. (2025). Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype. MED, 6(4) [10.1016/j.medj.2024.11.007]. Detail
Zapata Dongo, R., Fontana, D., Mologni, L., Faya Castillo, J., Infante, V. (2025). Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer. Intervento presentato a: Barcelona BioMed Conferences. AI in Drug Discovery and Biomedicine, Barcelona, Spain. Detail
Malighetti, F., Villa, M., Villa, A., Pelucchi, S., Aroldi, A., Cortinovis, D., et al. (2025). Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 26(5) [10.3390/ijms26051943]. Detail
Introvigne, M., Destro, L., Mologni, L., Crippa, V., Zardi, P., Fini, F., et al. (2025). α-Triazolylboronic Acids: A Novel Scaffold to Target FLT3 in AML. CHEMMEDCHEM, 20(1) [10.1002/cmdc.202400622]. Detail
Destro, L., Crippa, V., Gabbia, D., Roverso, M., Bogialli, S., Zardi, P., et al. (2025). Discovery of selective, metabolically stable pyrazole-based FLT3 inhibitors for the treatment of acute myeloid leukemia. RSC MEDICINAL CHEMISTRY, 16(4), 1766-1780 [10.1039/d4md00956h]. Detail